Atosiban, CAS 90779-69-4, Pharmaceutical Peptide

• Powder: Yes
• Customized: Customized
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Adult
• State: Solid
• Purity: >98%
• Model NO.: HJYY
• appearance: White Powder
• Assay: 98%
• Water: Not More Than 5%
• Impurity: Not More Than 2%
• Transport Package: 10g/Al Bag
• Specification: 98%
• Trademark: HD
• Origin: China
• HS Code: 2937190090
• Production Capacity: 100000g/Month

Product Description

   

Product Description

Atosiban (RW22164; RWJ22164) is a nonapeptide competitive vasopressin/oxytocin receptor antagonist, and is a desamino-oxytocin analogue. Atosiban is the main tocolytic agent and has the potential for spontaneous preterm labor research.

Detailed Photos

Product Parameters

Product Info

 

Generic name	Atosiban
Synonyms	ORF-22164; ORF 22164; ORF22164; RWJ-22164; RWJ 22164; RWJ22164; Atosiban.   trade names Tractocile, Antocin, atosiban SUN.
Formula	C43H67N11O12S2
CAS No.	90779-69-4
Molecular Weight	994.19
EINECS	806-815-5

  Chemical Properties

Density	1.254±0.06 g/cm3(Predicted)
Melting Point	>165oC (dec.)
Boling Point	1469.0±65.0 °C(Predicted)
Flash Point	842.2°C
Solubility	H2O: ≤100mg/mL
Refractive Index	1.549
Storage Condition	-20°C
pka	12.81±0.70(Predicted)
Apperance	Solid, White to Off-White

Application & Efficacy

       Atosiban is an antagonist of a combination of oxytocin and vasopressin V1A receptors, which are structurally similar to the vasopressin V1A receptor. When the oxytocin receptor is blocked, oxytocin can still play a role through the V1A receptor, so it is necessary to block the above two receptor pathways at the same time, and a single antagonist can effectively inhibit uterine contraction. This is one of the main reasons why β-agonists, calcium channel blockers and prostaglandin synthetase inhibitors do not effectively inhibit uterine contractions. Competitive antagonist of the cyclic peptide oxytocin receptor in uterus, decidua and fetal membranes.